SOSV

Atlantic Fish Company is focused on producing cultivated seafood through cellular agriculture, operating from its headquarters in Raleigh-Durham, North Carolina. The company aims to provide sustainable seafood options by cultivating fish in a controlled environment. This innovative approach allows Atlantic Fish Company to offer fresh fish meat that maintains the natural taste while minimizing the environmental impact associated with traditional fishing practices. By leveraging cellular agriculture, the company seeks to meet the growing demand for sustainable protein sources.

Atlantic Fish Company is focused on producing cultivated seafood through cellular agriculture, operating from its headquarters in Raleigh-Durham, North Carolina. The company aims to provide sustainable seafood options by cultivating fish in a controlled environment. This innovative approach allows Atlantic Fish Company to offer fresh fish meat that maintains the natural taste while minimizing the environmental impact associated with traditional fishing practices. By leveraging cellular agriculture, the company seeks to meet the growing demand for sustainable protein sources.

Atlantic Fish Company is focused on producing cultivated seafood through cellular agriculture, operating from its headquarters in Raleigh-Durham, North Carolina. The company aims to provide sustainable seafood options by cultivating fish in a controlled environment. This innovative approach allows Atlantic Fish Company to offer fresh fish meat that maintains the natural taste while minimizing the environmental impact associated with traditional fishing practices. By leveraging cellular agriculture, the company seeks to meet the growing demand for sustainable protein sources.

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

Prospective Research, Inc., based in Beverly, Massachusetts, specializes in developing innovative solutions for antibiotic discovery and disease management in aquaculture. Founded in 2015, the company utilizes its proprietary MicrobeMiner platform to access untapped antibiotics by mimicking natural soil stimuli. Its GeneMiner technology aligns specific microbes with targeted stimuli, while the StimKeys technology reproduces these stimuli to unlock microbial natural products. Additionally, Prospective Research is pioneering feed-integrated preventative disease management solutions that eliminate the need for traditional antibiotics in aquaculture. By employing microbial signaling molecules, the company can modulate bacterial behavior and deliver therapeutics directly to the gut of farmed species. Prospective Research introduces trillions of beneficial bacteria into the microbiome of fin-fish, shrimp, and shellfish, enabling selective activation of bacterial genes that produce bio-active therapeutics to combat various pathogens.

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

Plantruption builds a brand of sustainability to develop products using seaweed and microalgae. The company is on a mission to create the first plant-based seafood. It researches and collaborates with universities and food technologists to provides Plant-based seafood that’s close in taste and texture to the real deal. Plant-based seafood provides a host of environmental benefits, including alleviating pressures on rapidly depleting fisheries, providing relief to fragile ocean ecosystems, reducing the impact of fishing nets on the ocean plastic problem, and reducing production emissions. The company was founded in 2019 in Dublin, Dublin.

New Wave Foods, Inc., established in 2015 and headquartered in San Francisco, specializes in producing and selling plant-based seafood products. The company offers a range of shrimp alternatives, including sautéed, grilled, breaded, and fried options, as well as shrimp tacos and salads. These products are made from sustainably sourced seaweed, soy protein, and natural flavors, providing a sustainable and healthier alternative to traditional seafood. New Wave Foods serves customers in the culinary market across the United States, positioning itself as a leader in sustainable seafood.

BioFeyn develops aquafeed ingredients that enhance the nutrition and sustainability of farmed fish. By optimizing marine ingredients and applying biodegradable nanoencapsulation, the company improves digestion, absorption, and bioavailability of nutrients, enabling delivery to specific tissues. This targeted delivery supports healthier growth and disease prevention in fish while reducing environmental pollution. The approach combines modular nutrient delivery with natural disease preventatives, helping clients produce farmed fish that are both nutritious and more sustainable.

BioFeyn develops aquafeed ingredients that enhance the nutrition and sustainability of farmed fish. By optimizing marine ingredients and applying biodegradable nanoencapsulation, the company improves digestion, absorption, and bioavailability of nutrients, enabling delivery to specific tissues. This targeted delivery supports healthier growth and disease prevention in fish while reducing environmental pollution. The approach combines modular nutrient delivery with natural disease preventatives, helping clients produce farmed fish that are both nutritious and more sustainable.

MicroSynbiotiX Limited, founded in 2016 and based in Cork City, Ireland, focuses on the development of oral vaccines specifically for the aquaculture sector. The company leverages advancements in algal genomics and molecular biology to create engineered microalgae that can produce affordable therapeutic proteins and vaccines. This innovative approach serves to reduce the reliance on antibiotics in farmed fish, addressing significant issues such as high fish mortality rates and the risk of bacterial and viral diseases that threaten fish stocks. By utilizing microalgae as a delivery vehicle for these vaccines, MicroSynbiotiX not only minimizes labor and production costs but also enhances the accessibility and effectiveness of vaccines, ultimately contributing to improved global food security.

MicroSynbiotiX Limited, founded in 2016 and based in Cork City, Ireland, focuses on the development of oral vaccines specifically for the aquaculture sector. The company leverages advancements in algal genomics and molecular biology to create engineered microalgae that can produce affordable therapeutic proteins and vaccines. This innovative approach serves to reduce the reliance on antibiotics in farmed fish, addressing significant issues such as high fish mortality rates and the risk of bacterial and viral diseases that threaten fish stocks. By utilizing microalgae as a delivery vehicle for these vaccines, MicroSynbiotiX not only minimizes labor and production costs but also enhances the accessibility and effectiveness of vaccines, ultimately contributing to improved global food security.

Prospective Research, Inc., based in Beverly, Massachusetts, specializes in developing innovative solutions for antibiotic discovery and disease management in aquaculture. Founded in 2015, the company utilizes its proprietary MicrobeMiner platform to access untapped antibiotics by mimicking natural soil stimuli. Its GeneMiner technology aligns specific microbes with targeted stimuli, while the StimKeys technology reproduces these stimuli to unlock microbial natural products. Additionally, Prospective Research is pioneering feed-integrated preventative disease management solutions that eliminate the need for traditional antibiotics in aquaculture. By employing microbial signaling molecules, the company can modulate bacterial behavior and deliver therapeutics directly to the gut of farmed species. Prospective Research introduces trillions of beneficial bacteria into the microbiome of fin-fish, shrimp, and shellfish, enabling selective activation of bacterial genes that produce bio-active therapeutics to combat various pathogens.

MicroSynbiotiX Limited, founded in 2016 and based in Cork City, Ireland, focuses on the development of oral vaccines specifically for the aquaculture sector. The company leverages advancements in algal genomics and molecular biology to create engineered microalgae that can produce affordable therapeutic proteins and vaccines. This innovative approach serves to reduce the reliance on antibiotics in farmed fish, addressing significant issues such as high fish mortality rates and the risk of bacterial and viral diseases that threaten fish stocks. By utilizing microalgae as a delivery vehicle for these vaccines, MicroSynbiotiX not only minimizes labor and production costs but also enhances the accessibility and effectiveness of vaccines, ultimately contributing to improved global food security.

New Wave Foods, Inc., established in 2015 and headquartered in San Francisco, specializes in producing and selling plant-based seafood products. The company offers a range of shrimp alternatives, including sautéed, grilled, breaded, and fried options, as well as shrimp tacos and salads. These products are made from sustainably sourced seaweed, soy protein, and natural flavors, providing a sustainable and healthier alternative to traditional seafood. New Wave Foods serves customers in the culinary market across the United States, positioning itself as a leader in sustainable seafood.

Prospective Research, Inc., based in Beverly, Massachusetts, specializes in developing innovative solutions for antibiotic discovery and disease management in aquaculture. Founded in 2015, the company utilizes its proprietary MicrobeMiner platform to access untapped antibiotics by mimicking natural soil stimuli. Its GeneMiner technology aligns specific microbes with targeted stimuli, while the StimKeys technology reproduces these stimuli to unlock microbial natural products. Additionally, Prospective Research is pioneering feed-integrated preventative disease management solutions that eliminate the need for traditional antibiotics in aquaculture. By employing microbial signaling molecules, the company can modulate bacterial behavior and deliver therapeutics directly to the gut of farmed species. Prospective Research introduces trillions of beneficial bacteria into the microbiome of fin-fish, shrimp, and shellfish, enabling selective activation of bacterial genes that produce bio-active therapeutics to combat various pathogens.

MicroSynbiotiX Limited, founded in 2016 and based in Cork City, Ireland, focuses on the development of oral vaccines specifically for the aquaculture sector. The company leverages advancements in algal genomics and molecular biology to create engineered microalgae that can produce affordable therapeutic proteins and vaccines. This innovative approach serves to reduce the reliance on antibiotics in farmed fish, addressing significant issues such as high fish mortality rates and the risk of bacterial and viral diseases that threaten fish stocks. By utilizing microalgae as a delivery vehicle for these vaccines, MicroSynbiotiX not only minimizes labor and production costs but also enhances the accessibility and effectiveness of vaccines, ultimately contributing to improved global food security.

MicroSynbiotiX Limited, founded in 2016 and based in Cork City, Ireland, focuses on the development of oral vaccines specifically for the aquaculture sector. The company leverages advancements in algal genomics and molecular biology to create engineered microalgae that can produce affordable therapeutic proteins and vaccines. This innovative approach serves to reduce the reliance on antibiotics in farmed fish, addressing significant issues such as high fish mortality rates and the risk of bacterial and viral diseases that threaten fish stocks. By utilizing microalgae as a delivery vehicle for these vaccines, MicroSynbiotiX not only minimizes labor and production costs but also enhances the accessibility and effectiveness of vaccines, ultimately contributing to improved global food security.

Prospective Research, Inc., based in Beverly, Massachusetts, specializes in developing innovative solutions for antibiotic discovery and disease management in aquaculture. Founded in 2015, the company utilizes its proprietary MicrobeMiner platform to access untapped antibiotics by mimicking natural soil stimuli. Its GeneMiner technology aligns specific microbes with targeted stimuli, while the StimKeys technology reproduces these stimuli to unlock microbial natural products. Additionally, Prospective Research is pioneering feed-integrated preventative disease management solutions that eliminate the need for traditional antibiotics in aquaculture. By employing microbial signaling molecules, the company can modulate bacterial behavior and deliver therapeutics directly to the gut of farmed species. Prospective Research introduces trillions of beneficial bacteria into the microbiome of fin-fish, shrimp, and shellfish, enabling selective activation of bacterial genes that produce bio-active therapeutics to combat various pathogens.

New Wave Foods, Inc., established in 2015 and headquartered in San Francisco, specializes in producing and selling plant-based seafood products. The company offers a range of shrimp alternatives, including sautéed, grilled, breaded, and fried options, as well as shrimp tacos and salads. These products are made from sustainably sourced seaweed, soy protein, and natural flavors, providing a sustainable and healthier alternative to traditional seafood. New Wave Foods serves customers in the culinary market across the United States, positioning itself as a leader in sustainable seafood.

Prospective Research, Inc., based in Beverly, Massachusetts, specializes in developing innovative solutions for antibiotic discovery and disease management in aquaculture. Founded in 2015, the company utilizes its proprietary MicrobeMiner platform to access untapped antibiotics by mimicking natural soil stimuli. Its GeneMiner technology aligns specific microbes with targeted stimuli, while the StimKeys technology reproduces these stimuli to unlock microbial natural products. Additionally, Prospective Research is pioneering feed-integrated preventative disease management solutions that eliminate the need for traditional antibiotics in aquaculture. By employing microbial signaling molecules, the company can modulate bacterial behavior and deliver therapeutics directly to the gut of farmed species. Prospective Research introduces trillions of beneficial bacteria into the microbiome of fin-fish, shrimp, and shellfish, enabling selective activation of bacterial genes that produce bio-active therapeutics to combat various pathogens.